Disclosure of Share Capital and Voting Rights Outstanding as of September 30, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers) Paris, France (October 9, 2025 - 6:00 pm) – As of September 30, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as indicated below. Se ...

Core Viewpoint - PPG has launched a new non-methanol hard coating for ophthalmic lenses, addressing regulatory changes while ensuring durability performance [1] Company Summary - PPG introduced the PPG HI-GARD® Non-Methanol hard coating specifically for 1.5 standard index ophthalmic lenses [1] - The new formulation serves as a drop-in replacement for traditional methanol-based coatings, allowing prescription lens manufacturers to comply with evolving regulations [1] - The PPG Hi-Gard Non-Methanol coating provides the same level of scratch-resistant protection for plastic lens materials as its predecessors [1]

Core Points - As of August 31, 2025, EssilorLuxottica has a total of 463,145,529 shares outstanding [3] - The number of real voting rights, excluding treasury shares, is 461,157,737 [3] - The theoretical number of voting rights, including treasury shares, remains the same at 463,145,529 [3] - Voting rights for any shareholder are capped at 31%, as per the company's by-laws [3][2]

Core Insights - EssilorLuxottica has signed an agreement to acquire PUcore's division focused on the development, manufacturing, and sale of ophthalmic lens materials, enhancing its R&D and production capabilities for innovative high index lenses [1][2] - The acquisition includes a research and development unit, a materials production facility, and a sales office in South Korea, along with an intellectual property portfolio related to product formulations and production processes [2][3] - The transaction is expected to close by the end of 2025, pending regulatory approvals and customary closing conditions [4] Company Strategy - The acquisition aligns with EssilorLuxottica's commitment to improving standards in the research, development, and manufacturing of ophthalmic lenses, allowing the company to expand its portfolio of patents, technologies, and expertise [3] - By enhancing the production and formulation of high index monomers, the company aims to improve performance and sustainability across the ophthalmic industry [3]

Summary of Key Points Core Viewpoint - As of June 30, 2025, EssilorLuxottica has disclosed its share capital and voting rights, highlighting its position as a global leader in the ophthalmic lens, frame, and sunglasses market [2]. Group 1: Share Capital and Voting Rights - The total number of shares outstanding for EssilorLuxottica is 463,145,529 [3]. - The number of real voting rights, excluding treasury shares, is 461,150,585 [3]. - The theoretical number of voting rights, including treasury shares, remains at 463,145,529 [3]. - Voting rights for any shareholder are capped at 31%, as per the company's by-laws [3].

Summary of Key Points Core Viewpoint - As of May 31, 2025, EssilorLuxottica, a global leader in the design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses, disclosed its outstanding shares and voting rights [2]. Group 1: Share Capital and Voting Rights - Total shares outstanding amount to 457,507,201 [3]. - The number of real voting rights, excluding treasury shares, is 455,511,025 [3]. - The theoretical number of voting rights, including treasury shares, remains at 457,507,201 [3]. - Voting rights are capped at 31% for any shareholder, as per the company's by-laws [3].